Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing

Zusammenfassung

Comput Struct Biotechnol J. 2025 Nov 23;28:592–608. doi: 10.1016/j.csbj.2025.11.047 Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing Charlotte Maria Ursula Dette Charlotte Maria Ursula Dette aClinical Pharmacy, Saarland University, Saarbrücken 66123, Germany Find articles by Charlotte Maria Ursula Dette a,1, Veronika Alberg Veronika Alberg aClinical Pharmacy, Saarland University, Saarbrücken 66123, Germany Find articles by Veronika

Kerninformationen

Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart 70376, Germany cNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark dDivision of Diabetes, Endocrinology and Reproductive Biology, Ninewells Ho...

It identifies the limitations of these models that currently prevent them from qualifying as true DTs. Furthermore, this review discusses the potential advantages of DTs in drug development for new treatment strategies, disease progression modeling, and clinical decision support for RD research. Fin...

AI: artificial intelligence, DT: digital twin, MIDD: model-informed drug development, MIPD: model-informed precision dosing [1], [4].The number of publications on DTs in healthcare research has grown rapidly over the past 20 years (see Fig. 2), reflecting growing interest in DT-enabled drug developm...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen